Table of Contents
Chromatography Research International
Volume 2012 (2012), Article ID 273604, 6 pages
http://dx.doi.org/10.1155/2012/273604
Research Article

Development and Validation of a Stability-Indicating HPTLC Method for Analysis of Rasagiline Mesylate in the Bulk Drug and Tablet Dosage Form

1Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Amaravathi Road, Guntur 522002, India
2Department of Chemical Engineering, JNTU College of Engineering, Anantapur 515002, India
3Department of Pharmaceutical Analysis, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada 520008, India

Received 2 May 2011; Revised 18 July 2011; Accepted 2 October 2011

Academic Editor: Wenkui Li

Copyright © 2012 Singaram Kathirvel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Chen, D. M. Swope, and K. Dashtipour, “Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease,” Clinical Therapeutics, vol. 29, no. 9, pp. 1825–1849, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. Thébault, M. Guillaume, and R. Levy, “Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor,” Pharmacotherapy, vol. 24, no. 10, pp. 1295–1305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Fernández, E. Barcia, and S. Negro, “Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 5, pp. 1185–1191, 2009. View at Publisher · View at Google Scholar
  4. R. Narendrakumar, G. Nageswara Rao, and P. Y. Naidu, “Stability indicating RP-LC method for determination of rasagiline mesylate in bulk and pharmaceutical Dosage forms,” International Journal of Applied Biology and Pharmaceutical Technology, vol. 1, no. 2, pp. 247–259, 2010. View at Google Scholar
  5. M. Vijayalakshmi, J. V. L. N. Seshagiri Rao, and A. Lakshmana Rao, “Development and validation of RP-HPLC method for the estimation of rasagiline tablet dosage forms,” Rasayan Journal of Chemistry, vol. 3, no. 4, pp. 621–624, 2010. View at Google Scholar
  6. J. Chen, X. Duan, P. Deng, H. Wang, and D. Zhong, “Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to pharmacokinetic studies,” Journal of Chromatography B, vol. 873, no. 2, pp. 203–208, 2008. View at Google Scholar
  7. G. Devalarao, S. Kathirvel, and S. V. Satyanarayana, “Simple spectrophotometric methods for the determination of rasagiline mesylate in pharmaceutical dosage form,” Journal of Pharmacy Research, vol. 4, no. 1, pp. 61–62, 2011. View at Google Scholar
  8. B. Rama and K. Preeti, “UV Spectrophotometric method for the determination of rasagiline mesylate in bulk and pharmaceutical formulations,” International Journal of Pharmaceutical Sciences Review and Research, vol. 5, no. 1, pp. 5–7, 2010. View at Google Scholar
  9. G. Y. S. K. Swamy, K. Ravikumar, L. K. Wadhwa, R. Saxena, and S. Singh, “2R*,3R*,6S*-N,6-Bis(4-fluorophenyl)-2-(4-hydroxyphenyl)-3,4,5,6-tetrahydro-2H-pyran-3-carboxamide,” Acta Crystallographica Section E, vol. 61, no. 11, pp. 3608–3610, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. ICH, “Stability testing of new drug substances and products Q1A (R2),” in Proceedings of the International Conference on Harmonization, International Federation of Pharmaceutical Manufacturers and Association, Geneva, Switzerland, 2003.
  11. S. Singh and M. Bakshi, “Guidance on conduct of stress tests to determine inherent stability of drugs,” Pharmacy Technician Online, vol. 24, pp. 1–14, 2000. View at Google Scholar
  12. M. Bakshi and S. Singh, “Development of validated stability-indicating assay methods—critical review,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, pp. 1011–1040, 2002. View at Google Scholar
  13. ICH Topic Q2 (R1), Validation of analytical procedures: Methodology, Geneva, The European Agency for the Evaluation of Medicinal Products, September 2005.